PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy Adults
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT06659250
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
ATTR-CM: A Multi-country, Non-interventional Disease Registry
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 350
- Registration Number
- NCT06651073
Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06647654
- Locations
- 🇦🇷
Pfizer, Buenos Aires, Argentina
A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06646042
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults.
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06645938
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 723
- Registration Number
- NCT06641466
Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B
Not yet recruiting
- Conditions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT06634836
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 900
- Registration Number
- NCT06629779
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇺🇸AUC Urologists, LLC, Myrtle Beach, South Carolina, United States
🇺🇸Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, United States
A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia
Completed
- Conditions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1128
- Registration Number
- NCT06624020
- Locations
- 🇦🇺
Pfizer Australia, Sydney, New South Wales, Australia
A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1100
- Registration Number
- NCT06622109
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
© Copyright 2024. All Rights Reserved by MedPath